Headlines about Perrigo (NYSE:PRGO) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Perrigo earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.6899854751531 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern’s scoring:
- Cantor Fitzgerald Reiterates $107.00 Price Target for Perrigo (PRGO) (americanbankingnews.com)
- Perrigo Company (PRGO) EVP John Wesolowski Buys 700 Shares (americanbankingnews.com)
- Perrigo Co. Plc – Value Analysis (NYSE:PRGO) : December 19, 2017 (finance.yahoo.com)
- Perrigo seen acquiring Merck division for $4.7b – report (globes.co.il)
- Perrigo Co Plc (PRGO) Valuation Declined While Sg Americas Securities Has Trimmed by $1.48 Million Its Position … – Hill Country Times (hillcountrytimes.com)
PRGO has been the topic of several recent research reports. Cantor Fitzgerald set a $107.00 target price on shares of Perrigo and gave the stock a “buy” rating in a report on Monday, December 4th. Jefferies Group set a $71.00 price target on shares of Perrigo and gave the stock a “hold” rating in a research report on Sunday, October 29th. Argus upgraded shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research report on Friday, December 8th. UBS Group reiterated a “buy” rating and set a $98.00 price target (up previously from $84.00) on shares of Perrigo in a research report on Thursday, October 5th. Finally, Oppenheimer began coverage on shares of Perrigo in a research report on Thursday, September 7th. They set an “outperform” rating and a $88.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $92.13.
Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, November 9th. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.28. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the business posted $1.65 earnings per share. The company’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts expect that Perrigo will post 4.88 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, December 19th. Shareholders of record on Friday, December 1st were given a $0.16 dividend. The ex-dividend date was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.74%. Perrigo’s dividend payout ratio is currently -6.99%.
In other news, EVP John Wesolowski sold 388 shares of the firm’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.20, for a total transaction of $33,833.60. Following the completion of the transaction, the executive vice president now owns 248 shares of the company’s stock, valued at $21,625.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 1,051 shares of company stock worth $89,810 in the last 90 days. Company insiders own 6.90% of the company’s stock.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Perrigo (PRGO) Stock Price” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/23/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-perrigo-prgo-stock-price.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.